Morgan Stanley raised the firm’s price target on Dyne Therapeutics (DYN) to $50 from $46 and keeps an Overweight rating on the shares. Z-rostudirsen registrational expansion cohort data confirm robust dystrophin expression and “importantly” favorable functional benefits, says the analyst, who believes the data are supportive of accelerated approval with filing on track for Q2 of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target raised to $23 from $21 at Bernstein
- Dyne Therapeutics Amends Loan Agreement for $50 Million
- Dyne Therapeutics offers to sell $300M in common stock
- Dyne Therapeutics price target raised to $60 from $46 at H.C. Wainwright
- Dyne Therapeutics Reports Positive Phase 1/2 Trial Results